Health
SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3 | NEJM – nejm.org
Correspondence from The New England Journal of Medicine — SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
We conducted a global, randomized, placebo-controlled, phase 123 pivotal trial in which two 30-g doses of BNT162b2 (PfizerBioNTech) were administered 21 days apart (ClinicalTrials.gov number, NCT04368728). These doses of vaccine had mainly low-grade side…
Continue Reading
-
Business20 hours agoWhy is Alphabet stock worth less than Nvidia, Microsoft, Apple, and Amazon even though it is the most profitable S&P 500 company?
-
Noosa News19 hours ago‘Sunny, benign’ school holiday weather after morning showers in parts of Queensland
-
General14 hours agoDeveloper warns wind energy capacity may not be ready by WA coal deadline
-
Noosa News16 hours agoTips to improve engagement – Proctor